Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
针对新诊断的中国弥漫性大B细胞淋巴瘤患者,高剂量利妥昔单抗-CHOP方案与标准利妥昔单抗-CHOP方案的疗效比较:一项随机、多中心、开放标签的3期临床试验
期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2018.230
Li, Xueying; Huang, He; Xu, Bing; Guo, Hongqiang; Lin, Yingcheng; Ye, Sheng; Yi, Jiqun; Li, Wenyu; Wu, Xiangyuan; Wang, Wei; Zhan, Hongyu; Xie, Derong; Peng, Jiewen; Cao, Yabing; Pu, Xingxiang; Guo, Chengcheng; Hong, Huangming; Wang, Zhao; Fang, Xiaojie; Zhou, Yong; Lin, Suxia; Liu, Qing; Lin, Tongyu